The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
 
Mohamed Bouattour
Honoraria - Bayer Schering Pharma
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Speakers' Bureau - Bayer; Roche; SIRTEX Medical
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche
 
Juan W. Valle
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Boehringer Ingelheim; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks
Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche
 
Arndt Vogel
Honoraria - Advanced Accelerator Applications/Imaging Equipment Ltd; Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; Eisai; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo
Research Funding - Novartis
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
 
Masayuki Kitano
Honoraria - EA Pharma
Research Funding - Abbvie (Inst); Takeda (Inst)
 
Jen-Shi Chen
Research Funding - Amgen; Astellas Pharma; AstraZeneca; Janssen; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; Senhwa Biosciences; TTY Biopharm
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Research Funding - Abbvie (Inst); Agios (Inst); Archer (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); BioTheryX (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CALGB (Inst); CicloMed (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Harpoon therapeutics (Inst); Hengrui Therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst); XBiotech (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); GRAIL (Inst); Incyte (Inst); Novartis (Inst); TG Therapeutics (Inst); Vincerx Pharma (Inst)
 
Renata Zaucha
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Roche
Research Funding - Novartis (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Ludovic Evesque
Honoraria - AstraZeneca; SERVIER
 
David Bing Zhen
Consulting or Advisory Role - Cornerstone Pharmaceuticals; Ipsen; QED Therapeutics
Research Funding - AstraZeneca; Bristol Myers Squibb; Cornerstone Pharmaceuticals; Daiichi Sankyo/Astra Zeneca; Genentech; Legend Biotech; Lilly; Merck; Seagen; TME Pharma
 
Vineet Govinda Gupta
Stock and Other Ownership Interests - RPG Life Sciences; Zydus Lifesciences
 
Joon Oh Park
Consulting or Advisory Role - AstraZeneca; Celgene; MediRama; Merck Serono; SERVIER
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER
 
Magdalena Żotkiewicz
Employment - AstraZeneca
 
Nana Rokutanda
Employment - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Gordon Cohen
No Relationships to Disclose
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER